Psilocybin, Lp(a), CAC, Niere und Darmkrebs - Evidenz-Quickies KW12

Nach einer Pause gibt es heute wieder Evidenz-Quickies, und zwar gleich mehrere, dafür aber kürzer und weniger ausführlich als zuletzt. Und dieses Format ist jetzt zweigeteilt: (a) Für alle, denen die Nachricht genügt, gibt es oben die Quickies in Kürze. (b) Alle, die weiterlesen wollen, finden die detaillierten Fassungen unten. Viel Freude und hoffentlich i...

Raman Activity Investigation and Utilization of Psilocybin

ABSTRACT Accidental ingestion of psilocybin-containing mushrooms can cause poisoning and hallucinations, making their rapid detection a public health priority. Conventional methods such as HPLC, GC-MS, LC-MS, TLC, CE, and ELISA provide sensitivity but are often destructive, time-consuming, or impractical for real-time applications. This study introduces a Ra...

PSILOCYBIN AS AN ADJUNCTIVE TREATMENT FOR DEPRESSION AND PSYCHOLOGICAL DISTRESS IN ONCOLOGY: CURRENT EVIDENCE AND CLINICAL IMPLICATIONS

Depression and psychological distress are highly prevalent among patients with cancer and are associated with impaired quality of life, reduced treatment adherence, and poorer clinical outcomes. Standard pharmacological and psychosocial interventions often demonstrate limited efficacy or delayed onset of action in oncological and palliative settings. Psilocy...

Explainable AI framework for psilocybin depression treatment optimization

Introduction This computational modeling study introduces a novel Explainable Artificial Intelligence (XAI) framework for optimizing single-dose psilocybin treatment protocols through personalized intervention modeling using publicly available mental health datasets. All results presented are derived from novel simulated data and predictive modeling only, no...

Behavioural investigations of psilocybin in non-human animals 1962-2021: A scoping review

Abstract Background and Aims Psilocybin is a psychedelic compound that may hold promise for a wide range of human health conditions, yet the identification of therapeutic processes and mechanisms of action remains exploratory. We conducted a scoping review of pre-clinical behavioural investigations of psilocybin in non-human animals to identify behavioural e...

“Diversity makes the richness of humanity”: The emergence and persistence of mental imagery after self-reported psilocybin truffles intake in an autistic woman with “blind imagination” (aphantasia): A33-month retrospective case report

Abstract This 33-month retrospective case report explores the impact of psilocybin truffle intake on the emergence (and persistence) of mental imagery in an autistic woman with aphantasia. Aphantasia refers to the inability to generate visual mental images, which can significantly affect individuals' experiences and cognitive processes. The case study focuse...

Psilocybin Reshapes Anterior Cingulate Network Neuropathic Topology to Reduce Chronic Pain

MedCheck: FDA Reviews NDA for Narcolepsy Drug, Green-Lights Psilocybin Trial for PTSD, and More

Journeying into Right Relations: Scientists Turn to Psilocybin to Shift Psychological Burdens of Global Environmental Change and Find Transformational Pathways Forward

This paper follows 8 scientists who ventured into the world of psychedelics on a quest to find transformational pathways forward. Each have worked on aspects of global environmental change for decades, and observing environmental crises converging into a global polycrisis/metacrisis with genuine potential for collapse, we have all carried psychological burde...

Effects of Psilocybin and Select Pharmaceutical Interactions

In Canada, the use of both prescription medications and psychedelics has become increasingly prevalent. As of 2022, approximately 16.5% of Canadians-about 6.3 million individuals-were prescribed at least one antidepressant, with fluoxetine remaining one of the most commonly used options (IQVIA, 2023). Benzodiazepine use, including drugs like alprazolam, rang...

Low-income group psilocybin assisted therapy for depression: An Oregon feasibility study

Abstract Background and aims Despite growing popularity and increasing legal access, psychedelic therapy remains financially inaccessible to many. This study was designed to test the feasibility of conducting group psilocybin therapy in low-income adults with depression in Oregon's regulated psilocybin program. Methods An open label, uncontrolled design was ...

Psilocybin exerts differential effects on social behavior and inflammation in mice in contexts of activity-based anorexia

Psychedelics, particularly psilocybin, have shown therapeutic potential across several psychiatric conditions, including depression, anxiety, obsessive-compulsive disorder, and anorexia nervosa (AN). These disorders often share social deficits that may be effectively alleviated by psychedelics considering their use has been linked with emotional empathy and ...

Computational Analysis of Psilocybin Effects on Three-Choice Touchscreen Reversal Learning in Rats: A Pilot Study

Introduction: Cognitive flexibility is essential for behavioral adaptation in response to environmental changes and is impaired in various neuropsychiatric disorders. The serotonergic psychedelic psilocybin has shown potential in enhancing cognitive flexibility, although with mixed results. In this study, we investigated the effects of psilocybin on cognitiv...

Psilocybin wirkt bei therapieresistenter Depression

Ketamine and psilocybin for athletes: A therapeutic breakthrough or a slippery slope?

Attitudes and perceptions of Portuguese mental health professionals on the therapeutic use of psilocybin and methylenedioxymethamphetamine (MDMA).

Psilocybin-Induced Neuroplasticity and Sustained Antidepressant Effects

Psilocybin-assisted interventions have shown rapid reductions in depressive symptoms in controlled clinical settings, raising questions about biological mechanisms supporting durability beyond the acute drug effect. [5,7] Mechanistic accounts increasingly focus on neuroplasticity as a candidate pathway linking transient serotonergic receptor activation to lo...

PSILOCYBIN IN PSYCHIATRIC PRACTICE AND PSYCHEDELIC-ASSISTED THERAPY FOR TREATMENT-RESISTANT DEPRESSION

This manuscript comprehensively reviews psilocybin-assisted therapy for major depressive disorder and treatment-resistant depression. It aims to synthesize current understanding regarding its mechanisms, efficacy, safety, costs, and accessibility, comparing it with conventional antidepressant and ketamine treatments. The methodology involved a narrative synt...

Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Anxiety and Depression: A Rite of Passage Facilitation Model for a Phase 1/2 Study

Background: Psilocybin therapy is an emerging treatment for cancer-related anxiety, depression, and existential distress. Most clinical trials to date have studied individual models of psilocybin therapy, but group models may offer increased access and benefits of community. Purpose: This technical report describes a group facilitation model developed for an...

The Evaluation of the Efficacy and Safety of the Use of Psilocybin in the Treatment of Adults with Treatment-Resistant Depression

Treatment-resistant depression (TRD) has been well-researched within scientific literature, although the therapeutic value of psilocybin is not fully understood. The aim of this systematic review is to determine a stable and effective dosage unit to inform health professionals of the benefits of psilocybin, using peer-reviewed literature and meta-analysis. T...